Related Experiment Video
Updated: Sep 27, 2026

Du-Moxibustion in a Mouse Model of Ankylosing Spondylitis
Published on: October 27, 2023
Ankylosing spondylitis: a beta2m-deposition disease?
Barbara Uchanska-Ziegler1, Andreas Ziegler
1Institut für Immungenetik, Universitätsklinikum Charité, Humboldt-Universität zu Berlin, Spandauer Damm 130, 14050 Berlin, Germany. barbara.uchanska-ziegler@charite.de
Abstract:
To explain the strong association between HLA-B27 and ankylosing spondylitis, we suggest that the release of beta(2)-microglobulin (beta(2)m) from a subpopulation of cell surface-expressed HLA-B27 molecules leads to beta(2)m-deposition within synovia and to the initiation of an inflammatory process, which culminates in destructive spondyloarthropathy.
Insights
The study proposes that beta(2)-microglobulin release from HLA-B27 molecules triggers inflammation, explaining the link between HLA-B27 and ankylosing spondylitis. This process leads to joint damage in spondyloarthropathy.
Area of Science:
- Immunogenetics
- Rheumatology
- Molecular Biology
Background:
- The human leukocyte antigen B27 (HLA-B27) is strongly associated with ankylosing spondylitis.
- The exact mechanism linking HLA-B27 to the disease remains incompletely understood.
Purpose of the Study:
- To elucidate the molecular mechanism underlying the association between HLA-B27 and ankylosing spondylitis.
Main Methods:
- The study suggests a hypothesis involving the release of beta(2)-microglobulin (beta(2)m) from HLA-B27 molecules.
- This release is proposed to occur from a subpopulation of cell surface-expressed HLA-B27.
Main Results:
- The proposed mechanism involves beta(2)m deposition within synovial tissues.
- This deposition is hypothesized to initiate an inflammatory cascade.
Conclusions:
- The release of beta(2)m from HLA-B27 molecules is suggested as a key factor in the pathogenesis of ankylosing spondylitis.
- This process culminates in destructive spondyloarthropathy.
Related Concept Videos
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Myasthenia Gravis ll: Pathophysiology
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Degenerative Disc Disease ll: Pathophysiology
